Hudson Bay Capital Management
CERE

Hudson Bay Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Hudson Bay Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-475,000
Closed -$19.4M – 1113
2024
Q2 		$19.4M Buy
475,000
+251,926
+113% +$10.5M 0.09% 142
2024
Q1 		$9.43M Buy
223,074
+135,674
+155% +$5.7M 0.05% 181
2023
Q4 		$3.71M Buy
87,400
+37,400
+75% +$1.07M 0.02% 356
2023
Q3 		$1.09M Buy
+50,000
New +$1.25M 0.01% 549
2023
Q2 		– Sell
-40,000
Closed -$976K – 1024
2023
Q1 		$976K Sell
40,000
-10,000
-20% -$293K 0.01% 593
2022
Q4 		$1.58M Buy
50,000
+5,000
+11% +$141K 0.02% 637
2022
Q3 		$1.27M Buy
+45,000
New +$1.34M 0.01% 817
2020
Q4 		– Sell
-153,984
Closed -$1.61M – 734
2020
Q3 		$1.61M Buy
+153,984
New +$1.62M 0.02% 383

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Hudson Bay Capital Management's CERE Position: Q3 2024 in Review

Hudson Bay Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 475,000 shares — an estimated $19.4M sold.

Hudson Bay Capital Management first reported a position in CERE in Q3 2020 and held it in 8 quarters. The position peaked at $19.4M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Hudson Bay Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 475,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $19.4M.
  • Hudson Bay Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 8 quarters.
  • Hudson Bay Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $19.4M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Hudson Bay Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.